Fri, 25 Apr 2008 16:45:09 -0400 MBL Communications http://psychcast.mblcommunications.com Podcast Maker v1.2.8a - http://www.potionfactory.com/podcastmaker PsychCast™ is designed to enable physicians to simply and easily listen to a compilation of insightful, 20-35 minute interviews with internationally recognized researchers and clinicians in the fields of psychiatry and neuropsychiatry. Expert interviews are gathered from Primary Psychiatry, The Largest Peer Reviewed Psychiatric Journal in the Nation, and CNS Spectrums, The International Journal of Neuropsychiatric Medicine. Additional PsychCast™ programming includes peer-reviewed expert panel dialogues, case-based psychopharmacology lessons, and CME-accredited educational programs designed to provide our 115,000+ monthly readers with an additional level of personalization in the era of multi-channel learning. PsychCast™ is designed to enable physicians to simply and easily listen to a compilation of insightful, 20-35 minute interviews with internationally recognized researchers and clinicians in the fields of psychiatry and neuropsychiatry. Expert interviews are gathered from Primary Psychiatry, The Largest Peer Reviewed Psychiatric Journal in the Nation, and CNS Spectrums, The International Journal of Neuropsychiatric Medicine. Additional PsychCast™ programming includes peer-reviewed expert panel dialogues, case-based psychopharmacology lessons, and CME-accredited educational programs designed to provide our 115,000+ monthly readers with an additional level of personalization in the era of multi-channel learning. en 2007 MBL Communications MBL Communications info@mblcommunications.com http://psychcast.mblcommunications.com/audio/PsychCast1_144.jpg http://psychcast.mblcommunications.com 144 130 Medicine cme,interviews,psychology,psychiatry no MBL Communications Dr. Diem is Assistant Professor of Medicine at the University of Minnesota. She is a general internist, epidemiologist, and clinical trialist of women’s health. In addition, her clinical practice is primarily focused on perimenopausal and postmenopausal women. Dr. Diem is co-investigator on the Study of Osteoporotic Fractures, a prospective cohort study funded by the National Institutes of Health that examines the risk factors for osteoporosis and fractures in postmenopausal women. Depression, Antidepressants, and Bone Loss Dr. Diem is Assistant Professor of Medicine at the University of Minnesota. She is a general internist, epidemiologist, and clinical trialist of women’s health. In addition, her clinical practice is primarily focused on perimenopausal and postmenopausal women. Dr. Diem is co-investigator on the Study of Osteoporotic Fractures, a prospective cohort study funded by the National Institutes of Health that examines the risk factors for osteoporosis and fractures in postmenopausal women. http://psychcast.mblcommunications.com/audio/18diem.m4a Fri, 25 Apr 2008 16:41:03 -0400 Medicine no 00:13:09 cme,interviews,psychology,psychiatry MBL Communications Dr. Clayton is David C. Wilson professor of psychiatry and professor of clinical obstetrics and gynecology at the University of Virginia in Charlottesville. She is distinguished fellow of the American Psychiatric Association and certified by the American Board of Psychiatry and Neurology. Dr. Clayton is consulting editor for the Journal of Sex & Marital Therapy and received the Columnist of the Year award in 2005 for her bi-monthly column in Primary Psychiatry, “Considerations in Women’s Mental Health.” In 2007, her book, Satisfaction: Women, Sex and the Quest for Intimacy, was published for the general public. An Update on the Sexual Side Effects of Medication Dr. Clayton is David C. Wilson professor of psychiatry and professor of clinical obstetrics and gynecology at the University of Virginia in Charlottesville. She is distinguished fellow of the American Psychiatric Association and certified by the American Board of Psychiatry and Neurology. Dr. Clayton is consulting editor for the Journal of Sex & Marital Therapy and received the Columnist of the Year award in 2005 for her bi-monthly column in Primary Psychiatry, “Considerations in Women’s Mental Health.” In 2007, her book, Satisfaction: Women, Sex and the Quest for Intimacy, was published for the general public. http://psychcast.mblcommunications.com/audio/17Clayton.m4a Fri, 14 Mar 2008 02:16:19 -0400 Medicine no 00:19:04 cme,interviews,psychology,psychiatry MBL Communications Dr. Janicak is professor of Psychiatry at Rush University in Chicago, Illinois, medical director of the Rush Psychiatric Clinical Research Center, and distinguished fellow at the American Psychiatric Association. He has been listed in Best Doctors of America since 1996 and Who’s Who in America since 2002. In 2003, the Illinois chapter of the National Alliance for the Mentally Ill named Dr. Janicak “Psychiatrist of the Year.” With a strong interest in the assessment and treatment of mood and psychotic disorders, he has been a National Institute of Mental Health grant awardee as both principal and co-investigator. Dr. Janicak is editor of the Psychopharm Review and has authored >250 publications in psychiatric literature, including Principles and Practice of Psychopharmacotherapy. Neuromodulation Dr. Janicak is professor of Psychiatry at Rush University in Chicago, Illinois, medical director of the Rush Psychiatric Clinical Research Center, and distinguished fellow at the American Psychiatric Association. He has been listed in Best Doctors of America since 1996 and Who’s Who in America since 2002. In 2003, the Illinois chapter of the National Alliance for the Mentally Ill named Dr. Janicak “Psychiatrist of the Year.” With a strong interest in the assessment and treatment of mood and psychotic disorders, he has been a National Institute of Mental Health grant awardee as both principal and co-investigator. Dr. Janicak is editor of the Psychopharm Review and has authored >250 publications in psychiatric literature, including Principles and Practice of Psychopharmacotherapy. http://psychcast.mblcommunications.com/audio/16janicak.m4a Fri, 15 Feb 2008 00:02:24 -0500 Medicine no 00:34:39 cme,interviews,psychology,psychiatry MBL Communications Dr. Sadock is Menas S. Gregory professor of psychiatry and vice chairman at the New York University (NYU) School of Medicine. He is attending psychiatrist at the Bellevue and Tisch Hospitals and is consulting psychiatrist at Lenox Hill Hospital. Dr. Sadock is diplomate of the American Board of Psychiatry and Neurology and Distinguished Life Fellow of the American Psychiatric Association. He is also president and founder of the NYU-Bellevue Psychiatric Society. He was appointed Faculty Scholar at the NYU School of Medicine in 2000. Dr. Sadock is author and editor of over 100 publications and book reviewer for psychiatric journals, including the American Journal of Psychiatry. The Comprehensive Textbook of Psychiatry, 8th Edition Dr. Sadock is Menas S. Gregory professor of psychiatry and vice chairman at the New York University (NYU) School of Medicine. He is attending psychiatrist at the Bellevue and Tisch Hospitals and is consulting psychiatrist at Lenox Hill Hospital. Dr. Sadock is diplomate of the American Board of Psychiatry and Neurology and Distinguished Life Fellow of the American Psychiatric Association. He is also president and founder of the NYU-Bellevue Psychiatric Society. He was appointed Faculty Scholar at the NYU School of Medicine in 2000. Dr. Sadock is author and editor of over 100 publications and book reviewer for psychiatric journals, including the American Journal of Psychiatry. http://psychcast.mblcommunications.com/audio/15sadock.m4a Wed, 30 Jan 2008 15:16:45 -0500 Medicine no 00:28:15 cme,interviews,psychology,psychiatry MBL Communications Dr. Thase is professor of psychiatry at the University of Pennsylvania School of Medicine in Philadelphia. He is a distinguished fellow of the American Psychiatric Association and a founding fellow of the Academy of Cognitive Therapy, a non-profit mental health organization dedicated to serving people with mental health disorders. He is director of the American Society of Clinical Psychopharmocology and vice chairman on the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase’s research centers on the evaluation and treatment of mood disorders. Examining the Strengths and Limitations of Generic Formulations of Antidepressants Dr. Thase is professor of psychiatry at the University of Pennsylvania School of Medicine in Philadelphia. He is a distinguished fellow of the American Psychiatric Association and a founding fellow of the Academy of Cognitive Therapy, a non-profit mental health organization dedicated to serving people with mental health disorders. He is director of the American Society of Clinical Psychopharmocology and vice chairman on the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase’s research centers on the evaluation and treatment of mood disorders. http://psychcast.mblcommunications.com/audio/14Thase.m4a Sun, 06 Jan 2008 02:23:25 -0500 Medicine no 00:22:16 cme,interviews,psychology,psychiatry MBL Communications Dr. Goldberg is director of the Affective Disorders Program at Silver Hill Hospital in New Canaan, Connecticut, and associate clinical professor of psychiatry at the Mount Sinai School of Medicine in New York City. His research focuses on the treatment and clinical features of bipolar disorder. He is a co-investigator in the National Institute of Mental Health (NIMH) Systematic Treatment Enhancement Program for Bipolar Disorder and has received a Career Development Award from the NIMH. He has also received research grants from the National Alliance for Research in Schizophrenia and Depression, the American Foundation for Suicide Prevention, and the Stanley Foundation. Bipolar Disorder Dr. Goldberg is director of the Affective Disorders Program at Silver Hill Hospital in New Canaan, Connecticut, and associate clinical professor of psychiatry at the Mount Sinai School of Medicine in New York City. His research focuses on the treatment and clinical features of bipolar disorder. He is a co-investigator in the National Institute of Mental Health (NIMH) Systematic Treatment Enhancement Program for Bipolar Disorder and has received a Career Development Award from the NIMH. He has also received research grants from the National Alliance for Research in Schizophrenia and Depression, the American Foundation for Suicide Prevention, and the Stanley Foundation. http://psychcast.mblcommunications.com/audio/13Goldberg.m4a Wed, 21 Nov 2007 02:04:07 -0500 Medicine no 00:37:06 cme,interviews,psychology,psychiatry MBL Communications Dr. Marder is professor at the Semel Institute of Neuroscience and Human Behavior at the University of California, Los Angeles (UCLA); director of the Veterans Integrated Service Network 22 Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs in Los Angeles; and director of the Section on Psychosis at the UCLA Semel Institute. Dr. Marder’s research has focused on the treatment of schizophrenia and the pharmacology of antipsychotics. Newer Antipsychotics and the Differences Between Clinical Experiences and Clinical Trials Dr. Marder is professor at the Semel Institute of Neuroscience and Human Behavior at the University of California, Los Angeles (UCLA); director of the Veterans Integrated Service Network 22 Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs in Los Angeles; and director of the Section on Psychosis at the UCLA Semel Institute. Dr. Marder’s research has focused on the treatment of schizophrenia and the pharmacology of antipsychotics. http://psychcast.mblcommunications.com/audio/12Marder.m4a Mon, 15 Oct 2007 12:26:38 -0400 Medicine no 00:25:13 cme,interviews,psychology,psychiatry MBL Communications Dr. Wray is a statistical geneticist specializing in the genetics of complex diseases. She is senior research officer at Queensland Institute of Medical Research in Brisbane, Australia, where she leads the Anxiety and Depression Study of the Genetic Epidemiology Laboratory. The study represents a powerful design to identify a large cohort of individuals for genetic analysis for whom comorbidity between depression and anxiety subtypes is fully documented. This interview was conducted by Norman Sussman, MD, on May 2, 2007, and is published in the September 2007 Primary Psychiatry. Disclosure: Dr. Wray receives grant support from the Australian National Health and Medical Research Council, the National Institutes of Health, and Sequenom, Inc. Anxiety and Comorbid Measures Associated with Plexin A2 Dr. Wray is a statistical geneticist specializing in the genetics of complex diseases. She is senior research officer at Queensland Institute of Medical Research in Brisbane, Australia, where she leads the Anxiety and Depression Study of the Genetic Epidemiology Laboratory. The study represents a powerful design to identify a large cohort of individuals for genetic analysis for whom comorbidity between depression and anxiety subtypes is fully documented. This interview was conducted by Norman Sussman, MD, on May 2, 2007, and is published in the September 2007 Primary Psychiatry. Disclosure: Dr. Wray receives grant support from the Australian National Health and Medical Research Council, the National Institutes of Health, and Sequenom, Inc. http://psychcast.mblcommunications.com/audio/11Wray.m4a Wed, 19 Sep 2007 19:08:40 -0400 Medicine no 00:28:51 cme,interviews,psychology,psychiatry MBL Communications Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute in New York City. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia, and serves as the principal investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the National Institute of Mental Health. Dr. Lieberman’s research focuses on the neurobiology, pharmacology, and treatment of schizophrenia and related psychotic disorders. Tardive Dyskinesia Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute in New York City. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia, and serves as the principal investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the National Institute of Mental Health. Dr. Lieberman’s research focuses on the neurobiology, pharmacology, and treatment of schizophrenia and related psychotic disorders. http://psychcast.mblcommunications.com/audio/10Leberman.m4a Tue, 28 Aug 2007 20:12:12 -0400 Medicine no 00:25:08 cme,interviews,psychology,psychiatry MBL Communications Dr. Regier is executive director of the American Psychiatric Institute for Research and Education and director of the Division of Research at the American Psychiatric Association. During his 25 years at the National Institute of Mental Health, Dr. Regier was involved with the World Health Organization in international programs on the classification of mental disorders. He currently serves as vice chair of the task force to develop the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. This interview was conducted by Norman Sussman, MD, on April 16, 2007, and is published in the July 2007 Primary Psychiatry. Disclosure: Dr. Regier oversees all federal- and industry-sponsored research and research training grants at the American Psychiatric Institute for Research and Education but receives no external salary funding or honoraria from any government or industry sources. The Developmental Process for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Dr. Regier is executive director of the American Psychiatric Institute for Research and Education and director of the Division of Research at the American Psychiatric Association. During his 25 years at the National Institute of Mental Health, Dr. Regier was involved with the World Health Organization in international programs on the classification of mental disorders. He currently serves as vice chair of the task force to develop the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. This interview was conducted by Norman Sussman, MD, on April 16, 2007, and is published in the July 2007 Primary Psychiatry. Disclosure: Dr. Regier oversees all federal- and industry-sponsored research and research training grants at the American Psychiatric Institute for Research and Education but receives no external salary funding or honoraria from any government or industry sources. http://psychcast.mblcommunications.com/audio/09Reiger.m4a Sat, 14 Jul 2007 13:27:35 -0400 Medicine no 00:27:18 cme,interviews,psychology,psychiatry MBL Communications Dr. Joffe is professor of psychiatry at the University of Medicine and Dentistry of New Jersey and staff psychiatrist at The University Hospital, both in Newark. Dr. Joffe has been listed in The Best Doctors in America in 2005–2006. His research interests include depression, bipolar disorder, and psychoneuroendocrinology. This interview was conducted by Norman Sussman, MD, on January 26, 2007, and is published in the June 2007 Primary Psychiatry. Disclosure: Dr. Joffe reports no affiliation with or financial interest in any organization that may pose a conflict of interest. The Impact and Psychological Manifestations of Thyroid Dysfunction Dr. Joffe is professor of psychiatry at the University of Medicine and Dentistry of New Jersey and staff psychiatrist at The University Hospital, both in Newark. Dr. Joffe has been listed in The Best Doctors in America in 2005–2006. His research interests include depression, bipolar disorder, and psychoneuroendocrinology. This interview was conducted by Norman Sussman, MD, on January 26, 2007, and is published in the June 2007 Primary Psychiatry. Disclosure: Dr. Joffe reports no affiliation with or financial interest in any organization that may pose a conflict of interest. http://psychcast.mblcommunications.com/audio/08Joffe.m4a Thu, 14 Jun 2007 20:47:26 -0400 Medicine no 00:18:41 MBL Communications Dr. Whitlow is a dermatologist in private practice, and clinical associate professor of dermatology at New York University Medical Center, both in New York City. His clinical interests include allergic and immunologic skin disease. This interview was conducted by Norman Sussman, MD, on January 24, 2007, and is published in the May 2007 Primary Psychiatry. Disclosure: Dr. Whitlow is a consultant to Amgen. The Dermatological Side Effects of Pharmacologic Agents Dr. Whitlow is a dermatologist in private practice, and clinical associate professor of dermatology at New York University Medical Center, both in New York City. His clinical interests include allergic and immunologic skin disease. This interview was conducted by Norman Sussman, MD, on January 24, 2007, and is published in the May 2007 Primary Psychiatry. Disclosure: Dr. Whitlow is a consultant to Amgen. http://psychcast.mblcommunications.com/audio/07Whitlow.m4a Tue, 15 May 2007 20:06:41 -0400 Medicine no 00:19:36 MBL Communications Dr. Plakun is director of admissions and professional relations, a treatment team leader, psychotherapy supervisor, a member of the management group of the Erik H. Erikson Institute for Education and Research, and co-principal investigator of a prospective study of treatment outcome that utilizes objective measures of psychodynamic constructs at the Austen Riggs Center in Stockbridge, Massachusetts. He is also a distinguished fellow of the American Psychiatric Association and chair of its Committee on Psychotherapy by Psychiatrists. This interview was conducted by Norman Sussman, MD, on December 4, 2006, and is published in the April 2007 Primary Psychiatry. Disclosure: Dr. Plakun reports no affiliation with or financial interest in any organization that may pose a conflict of interest. The Impact of Suicide on Physicians Dr. Plakun is director of admissions and professional relations, a treatment team leader, psychotherapy supervisor, a member of the management group of the Erik H. Erikson Institute for Education and Research, and co-principal investigator of a prospective study of treatment outcome that utilizes objective measures of psychodynamic constructs at the Austen Riggs Center in Stockbridge, Massachusetts. He is also a distinguished fellow of the American Psychiatric Association and chair of its Committee on Psychotherapy by Psychiatrists. This interview was conducted by Norman Sussman, MD, on December 4, 2006, and is published in the April 2007 Primary Psychiatry. Disclosure: Dr. Plakun reports no affiliation with or financial interest in any organization that may pose a conflict of interest. http://psychcast.mblcommunications.com/audio/06Plakun.m4a Mon, 16 Apr 2007 16:40:02 -0400 Medicine no 00:24:18 MBL Communications Dr. Kellner is professor and chair of the Department of Psychiatry, and assistant dean for clinical research at the University of Medicine and Dentistry of New Jersey in Newark. He is also co-director of the electroconvulsive therapy (ECT) service at The University Hospital in Newark with George Petrides, MD, and was editor of The Journal of ECT from 1994–2004. Dr. Kellner’s ongoing research includes studies comparing different ECT types and methods for optimizing maintenance ECT. This interview was conducted by Norman Sussman, MD, on December 15, 2006, and is published in the March 2007 Primary Psychiatry. Disclosure: Dr. Kellner receives grant support from the National Center for Complementary and Alternative Medicine and the National Institute of Mental Health. Current Developments in Electroconvulsive Therapy Dr. Kellner is professor and chair of the Department of Psychiatry, and assistant dean for clinical research at the University of Medicine and Dentistry of New Jersey in Newark. He is also co-director of the electroconvulsive therapy (ECT) service at The University Hospital in Newark with George Petrides, MD, and was editor of The Journal of ECT from 1994–2004. Dr. Kellner’s ongoing research includes studies comparing different ECT types and methods for optimizing maintenance ECT. This interview was conducted by Norman Sussman, MD, on December 15, 2006, and is published in the March 2007 Primary Psychiatry. Disclosure: Dr. Kellner receives grant support from the National Center for Complementary and Alternative Medicine and the National Institute of Mental Health. http://psychcast.mblcommunications.com/audio/05Kellner.m4a Thu, 15 Mar 2007 23:21:24 -0400 Medicine no 00:26:45 MBL Communications Dr. Nierenberg is associate director of the Depression Clinical and Research Program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School in Boston. He is also director of the National Institute of Mental Health Bipolar Trials Network, a federally-funded infrastructure for the next generation of clinical trials to help patients with bipolar disorder. He was the site principal investigator for the Systematic Treatment Enhancement Program for Bipolar Disorder and was involved in the Sequenced Treatment Alternatives to Relieve Depression study. His research interests focus on bipolar disorder, treatment-resistant depression, and the longitudinal course of affective disorders. Dr. Nierenberg has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. This interview was conducted by Norman Sussman, MD, on December 8, 2006, and is published in the February 2007 Primary Psychiatry. Disclosure: Dr. Nierenberg is a consultant to BrainCells, Bristol-Myers Squibb, Eli Lilly, Genaissance, GlaxoSmithKline, Innapharma, Janssen, Novartis, Pfizer, Sepracor, Shire, and Somerset; receives grant support from Bristol-Myers Squibb, Cederroth, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lichtwer Pharma, the National Alliance for Research on Schizophrenia and Depression, the National Institute of Mental Health, Pfizer, the Stanley Foundation, and Wyeth; and receives honoraria from Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, and Wyeth. The Sequenced Treatment Alternatives to Relieve Depression Study: Recent Results Dr. Nierenberg is associate director of the Depression Clinical and Research Program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School in Boston. He is also director of the National Institute of Mental Health Bipolar Trials Network, a federally-funded infrastructure for the next generation of clinical trials to help patients with bipolar disorder. He was the site principal investigator for the Systematic Treatment Enhancement Program for Bipolar Disorder and was involved in the Sequenced Treatment Alternatives to Relieve Depression study. His research interests focus on bipolar disorder, treatment-resistant depression, and the longitudinal course of affective disorders. Dr. Nierenberg has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. This interview was conducted by Norman Sussman, MD, on December 8, 2006, and is published in the February 2007 Primary Psychiatry. Disclosure: Dr. Nierenberg is a consultant to BrainCells, Bristol-Myers Squibb, Eli Lilly, Genaissance, GlaxoSmithKline, Innapharma, Janssen, Novartis, Pfizer, Sepracor, Shire, and Somerset; receives grant support from Bristol-Myers Squibb, Cederroth, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lichtwer Pharma, the National Alliance for Research on Schizophrenia and Depression, the National Institute of Mental Health, Pfizer, the Stanley Foundation, and Wyeth; and receives honoraria from Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, and Wyeth. http://psychcast.mblcommunications.com/audio/04Nierenberg.m4a Thu, 22 Feb 2007 22:10:36 -0500 Medicine no 00:21:50 MBL Communications Dr. Weisler is adjunct professor of psychiatry at the University of North Carolina School of Medicine at Chapel Hill and adjunct associate professor of psychiatry and behavioral sciences at Duke University Medical Center in Durham. Also a private practitioner in Raleigh, North Carolina, Dr. Weisler has been a principal investigator in more than 200 clinical studies and was named one of America’s top psychiatrists for 2002–2003 by the Consumers’ Research Council of America. Dr. Weisler is currently working on a project with the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention to improve recognition and knowledge of disaster mental health for healthcare providers in the wake of Hurricanes Katrina and Rita. This interview was conducted by Norman Sussman, MD, on November 2, 2006, and is published in the January 2007 Primary Psychiatry. Disclosure: Dr. Weisler is a consultant to Agency of Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Bristol-Myers Squibb, Corcept, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, New River Pharmaceuticals, Novartis, Pfizer, sanofi-aventis, Shire, Solvay, and Wyeth; on the speaker’s bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, sanofi-aventis, Shire, Solvay, and Wyeth; receives grant or research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, MediciNova, Merck, the National Institute of Mental Health, Neurochem, New River Pharmaceuticals, Novartis, Pfizer, Saegis, sanofi-aventis, Shire, Solvay, Vela, and Wyeth; and owns stock in Bristol-Myers Squibb, Merck, and Pfizer. Treatment of Attention-Deficit/Hyperactivity Disorder Dr. Weisler is adjunct professor of psychiatry at the University of North Carolina School of Medicine at Chapel Hill and adjunct associate professor of psychiatry and behavioral sciences at Duke University Medical Center in Durham. Also a private practitioner in Raleigh, North Carolina, Dr. Weisler has been a principal investigator in more than 200 clinical studies and was named one of America’s top psychiatrists for 2002–2003 by the Consumers’ Research Council of America. Dr. Weisler is currently working on a project with the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention to improve recognition and knowledge of disaster mental health for healthcare providers in the wake of Hurricanes Katrina and Rita. This interview was conducted by Norman Sussman, MD, on November 2, 2006, and is published in the January 2007 Primary Psychiatry. Disclosure: Dr. Weisler is a consultant to Agency of Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Bristol-Myers Squibb, Corcept, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, New River Pharmaceuticals, Novartis, Pfizer, sanofi-aventis, Shire, Solvay, and Wyeth; on the speaker’s bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, sanofi-aventis, Shire, Solvay, and Wyeth; receives grant or research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, MediciNova, Merck, the National Institute of Mental Health, Neurochem, New River Pharmaceuticals, Novartis, Pfizer, Saegis, sanofi-aventis, Shire, Solvay, Vela, and Wyeth; and owns stock in Bristol-Myers Squibb, Merck, and Pfizer. http://psychcast.mblcommunications.com/audio/03Weisler.m4a Tue, 16 Jan 2007 16:17:04 -0500 Medicine no 00:31:04 MBL Communications Dr. Nelson is professor of psychiatry, director of geriatric psychiatry, and holds the Leon J. Epstein, MD, chair in geriatric psychiatry at the University of California, San Francisco. His research and expertise focus principally on the description and treatment of adult and geriatric depression, as well as the psychopharmacology of antidepressants. Among many accomplishments, Dr. Nelson received the Yale Residents Outstanding Teacher award in 1995 and 2001, and the Distinguished Yale Alumni Award in 2006. He wrote Geriatric Psychopharmacology in 1998. Dr. Nelson was one of the founding members of the American Society of Clinical Psychopharmacology and served as its president from 1999 to 2003. Treating Late-Life Depression Dr. Nelson is professor of psychiatry, director of geriatric psychiatry, and holds the Leon J. Epstein, MD, chair in geriatric psychiatry at the University of California, San Francisco. His research and expertise focus principally on the description and treatment of adult and geriatric depression, as well as the psychopharmacology of antidepressants. Among many accomplishments, Dr. Nelson received the Yale Residents Outstanding Teacher award in 1995 and 2001, and the Distinguished Yale Alumni Award in 2006. He wrote Geriatric Psychopharmacology in 1998. Dr. Nelson was one of the founding members of the American Society of Clinical Psychopharmacology and served as its president from 1999 to 2003. http://psychcast.mblcommunications.com/audio/02Nelson.m4a Wed, 13 Dec 2006 20:23:28 -0500 Medicine no 00:33:33 MBL Communications Treating Depression in Pregnancy Treating Depression in Pregnancy http://psychcast.mblcommunications.com/audio/podcast1.m4a Tue, 14 Nov 2006 21:04:01 -0500 Medicine no 00:25:47